To the best of our knowledge, this is the first clinical trial on NAFLD patients that compared the effect of pioglitazone and metformin on liver function tests (including AST, ALT, and ALP), metabolic profile (including FSG, HOMA-IR, and lipid profile), and LFC. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.